Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab followed by BGD chemotherapy and autologous stem cell transplantation for relapsed or refractory classical Hodgkin lymphoma
2021-002630-17Phase 2Active
- Sponsor
- Medical University of Gdańsk
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, bendamustine, gemcitabine and dexamethasone in classical Hodgkin lymphoma (cHL) and Hodgkin lymphoma (HL), sponsored by Medical University of Gdańsk. Primary endpoint: Complete Metabolic Remission rate. Started Nov 2021; status: active.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2021-002630-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002630-17.